Who are ICP-022's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): MGd, Acalabrutinib capsule, Ibrutinib (Maintenance), Zebutinib&BR or Zebutinib&FCR, LBL-007, Ibrutinib Oral Capsule.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/icp-022.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

ICP-022 — Competitive Intelligence Brief

ICP-022 (ICP-022) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bruton's tyrosine kinase (BTK) inhibitor. Area: Oncology.

phase 3 Bruton's tyrosine kinase (BTK) inhibitor BTK (Bruton's tyrosine kinase) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

ICP-022 (ICP-022) — Beijing InnoCare Pharma Tech Co., Ltd.. ICP-022 is a Bruton's tyrosine kinase (BTK) inhibitor that blocks BTK signaling to suppress B-cell and myeloid cell activation in hematologic malignancies.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
ICP-022 TARGET	ICP-022	Beijing InnoCare Pharma Tech Co., Ltd.	phase 3	Bruton's tyrosine kinase (BTK) inhibitor	BTK (Bruton's tyrosine kinase)
MGd	MGd	Pharmacyclics LLC.	marketed	Bruton's tyrosine kinase (BTK) inhibitor	BTK (Bruton's tyrosine kinase)
Acalabrutinib capsule	Acalabrutinib capsule	AstraZeneca	marketed	Bruton's tyrosine kinase (BTK) inhibitor	BTK (Bruton's tyrosine kinase)
Ibrutinib (Maintenance)	Ibrutinib (Maintenance)	Prof. Dr. M. Dreyling (co-chairman)	phase 3	Bruton's tyrosine kinase (BTK) inhibitor	BTK (Bruton's tyrosine kinase)
Zebutinib&BR or Zebutinib&FCR	Zebutinib&BR or Zebutinib&FCR	Nanfang Hospital, Southern Medical University	phase 3	Bruton's tyrosine kinase (BTK) inhibitor	BTK (Bruton's tyrosine kinase)
LBL-007	LBL-007	BeiGene	phase 3	Bruton's tyrosine kinase (BTK) inhibitor	BTK
Ibrutinib Oral Capsule	Ibrutinib Oral Capsule	Pharmacyclics LLC.	phase 3	Bruton's tyrosine kinase (BTK) inhibitor	BTK (Bruton's tyrosine kinase)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bruton's tyrosine kinase (BTK) inhibitor class)

AstraZeneca · 2 drugs in this class
Pharmacyclics LLC. · 2 drugs in this class
Prof. Dr. M. Dreyling (co-chairman) · 2 drugs in this class
BeiGene · 1 drug in this class
Beijing InnoCare Pharma Tech Co., Ltd. · 1 drug in this class
Nanfang Hospital, Southern Medical University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ICP-022 — Competitive Intelligence Brief. https://druglandscape.com/ci/icp-022. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab